Results 271 to 280 of about 512,327 (345)

Homozygous Achondroplasia With Long‐Term Survival: Growth Patterns, Medical Interventions, and Practice Implications

open access: yesAmerican Journal of Medical Genetics Part A, Volume 200, Issue 6, Page 1372-1377, June 2026.
ABSTRACT Homozygous achondroplasia is widely considered perinatal lethal by the medical community. In this case series, we report two children from a single family with longer‐term survival. One child lived for 17 months and the other was 60 months at the time of publication.
Hannah Singerline   +3 more
wiley   +1 more source

A depiction of areas significantly more activated in patients (blue) and controls (red) respectively during the psychomotor vigilance task performance.

open access: green
Anna Holmqvist (20234646)   +6 more
openalex   +1 more source

Genome Sequencing in 19 Families With Bladder Exstrophy and Epispadias Complex Indicates Involvement of the ADGR ‐Gene Family

open access: yesAmerican Journal of Medical Genetics Part A, Volume 200, Issue 6, Page 1286-1305, June 2026.
ABSTRACT Bladder exstrophy and epispadias complex (BEEC) is one of the most severe congenital malformations of the urogenital tract, significantly impacting continence, sexual function, and renal function. To date, the only recurrent genetic aberration identified is the 22q.11.2 microduplication, but several candidate regions and genes including ...
Agneta Nordenskjöld   +9 more
wiley   +1 more source

Cultivating Creative Potential: A Constraints‐Based Framework for Movement Exploration Instructions

open access: yesThe Journal of Creative Behavior, Volume 60, Issue 2, June 2026.
ABSTRACT How constraints affect individuals' creative potential interests many scientific fields. Education, especially after 2000, actively supports creativity promotion, with creativity occupying a prominent place in Physical Education (PE) curricula of many countries.
E. Konstantinidou
wiley   +1 more source

Beyond Diagnosis: Transdiagnostic Cognitive Subgroups in Mood Disorders Linked to Work‐Related Disability

open access: yesNeuropsychopharmacology Reports, Volume 46, Issue 2, June 2026.
Diagnostic categories alone did not explain differences in subjective social functioning, whereas cognitive clustering identified a lower‐performance subgroup with worse work and total disability. Cognitive heterogeneity may underlie functional impairment across mood disorders.
Ryo Sawagashira   +6 more
wiley   +1 more source

Akathisia Induced by Metoclopramide in a Pregnant Woman With Nausea and Vomiting: A Case Report

open access: yesNeuropsychopharmacology Reports, Volume 46, Issue 2, June 2026.
This case report describes a patient who was hospitalized at 33 weeks of gestation and diagnosed with metoclopramide‐induced akathisia. Although the akathisia symptoms resolved 3 days after discontinuation of metoclopramide, a possible interaction with dextromethorphan, which the patient had been orally administering prior to hospitalization, cannot be
Ryohei Nakamura   +6 more
wiley   +1 more source

The importance of longitudinal evaluation using DAT‐SPECT in organophosphate‐induced toxic parkinsonism

open access: yesPsychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
We performed longitudinal evaluation using magnetic resonance imaging (MRI) and dopamine transporter single‐photon emission computed tomography (DAT‐SPECT) in a case of organophosphate‐induced toxic parkinsonism. Fluid‐attenuated inversion recovery (FLAIR) images showed bilateral striatal hyperintensity in the acute phase, followed by reduction of ...
Shuhei Nakao   +6 more
wiley   +1 more source

Clinical dilemma of mood stabilizer augmentation in treatment‐resistant schizophrenia with residual phase: A case report of valproate‐associated hypoglycemia and cytopenia, and subsequent lithium response

open access: yesPsychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
Abstract Background Mood stabilizer augmentation is frequently used in treatment‐resistant schizophrenia despite limited guideline recommendations. Evidence for its efficacy and safety in the residual phase, however, remains insufficient. Case Presentation A 49‐year‐old Japanese woman with treatment‐resistant residual schizophrenia exhibited persistent
Yoshiki Kasagi   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy